Pulmonx Corporation (LUNG)
Nasdaq: LUNG · Surgical & Medical Instruments & Apparatus · Redwood City, CA · filing with the SEC since 2003
Who owns Pulmonx Corporation
As filed with the SECHolders of 5% or more
3
Primecap Management Co/ca/ holds 12.2% of COM, as its SCHEDULE 13G/A filed Nov 13, 2025 says.
Directors and officers
13
report now, of 16 people on the record since 2020. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 3 named at left.
Holders of 5% or moreshare of the class, as filed
Primecap Management Co/ca/
SCHEDULE 13G/A · filed Nov 13, 2025 · COM · 13.6% in May 13, 2025
Morgan Stanley
SCHEDULE 13G/A · filed Aug 13, 2026 · Common Stock · 8.5% in May 7, 2025
Soleus Capital Master Fund, L.P.
SCHEDULE 13G · filed Mar 9, 2026 · Common Stock, par value $0.001 per share
Blackrock, Inc.
SCHEDULE 13G/A · filed Jul 29, 2026 · Common Stock · reported falling below 5%, from 6.8% in Apr 24, 2025
Fmr LLC
SCHEDULE 13G/A · filed Nov 7, 2025 · COMMON STOCK · reported falling below 5%, from 5.4% in Sep 8, 2025
The Vanguard Group
SCHEDULE 13G/A · filed Mar 27, 2026 · Common Stock · reported falling below 5%
What LUNG reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
Emphasys Medical, Inc
A company bought · acquisition · owns, named in the 10-K filed Mar 10, 2026
8 subsidiaries in 8 countries, from the list filed with the 10-K filed Feb 25, 2025.
Insider tradesForm 4
55sales
0purchases
1sales on a scheduled plan
5people selling
$500,000sold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window5 of 17 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| French Glendon E. III | President and CEO | 10 | $300,000 | 0 | 0 | $0 |
| Radhakrishnan Srikanth | Chief Science & Techn. Officer | 12 | $100,000 | 0 | 0 | $0 |
| Rose Geoffrey Beran | Chief Commercial Officer | 16 | $100,000 | 0 | 0 | $0 |
| Lehman David Aaron | General Counsel | 16 | $100,000 | 0 | 0 | $0 |
| Florin Daniel P | director | 1 | $0 | 1 | 0 | $0 |